Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study

Authors
Category Primary study
ConferenceNeurology
Year 2024
This article has no abstract
Epistemonikos ID: f34d94332143dac5e43bb4cdb540bb066cb35696
First added on: Apr 30, 2026